Despite inducing Tregs, FL given prior to autologous phase accelerated anti-GBM GN did not result in significant protection from renal injury, although we found evidence that some elements of systemic immunity were attenuated, with reduced IL-17A production from splenocytes. This evidence concerns the gene IL17A and ganglioneuroma.